• Explore /
  • Poster
  • / Patients with metastatic renal cell carcinoma who have benefit from axitinib dose titration: Analysis from a randomized, double-blind, axitinib dose titration phase II study.

Patients with metastatic renal cell carcinoma who have benefit from axitinib dose titration: Analysis from a randomized, double-blind, axitinib dose titration phase II study.

Abstract Poster

Authors

null

Yoshihiko Tomita

Department of Urology, Department of Molecular Oncology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

Yoshihiko Tomita , Hirotsugu Uemura , Mototsugu Oya , Nobuo Shinohara , Tomonori Habuchi , Yosuke Fujii , Yoichi Kamei , Yoshiko Umeyama , A H. Bair , Brian I. Rini

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Penile, Urethral, and Testicular Cancers; Renal Cell Cancer

Track

Renal Cell Cancer,Penile, Urethral, and Testicular Cancers

Sub Track

Renal Cell Cancer

Clinical Trial Registration Number

NCT00835978

Citation

J Clin Oncol 35, 2017 (suppl 6S; abstract 438)

DOI

10.1200/JCO.2017.35.6_suppl.438

Abstract #

438

Poster Bd #

D1

Abstract Disclosures

Similar Posters

First Author: Brian I. Rini

First Author: Brian I. Rini

First Author: Sarmad Sadeghi

First Author: Simon J. Crabb